ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0204

Risk of Severe Infections Associated with Immunoglobulin Deficiency Under Rituximab Therapy in Immune Mediated Inflammatory Diseases
Abstract Number: 0205

Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy
Abstract Number: 0206

Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis
Abstract Number: 0207

Role of Pneumocystis Jirovecii Pneumonia Prophylaxis with Trimethoprim-Sulfamethoxazole Among Patients with Autoimmune Inflammatory Diseases Receiving High-Dose Glucocorticoids: A Systematic Review and Meta-Analysis
Abstract Number: 0208

Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis (PPX), Investigating the Practice Patterns of Providers for Patients on Chronic, High-Dose Immunosuppression in a Rural Integrated Health System
Abstract Number: 0209

Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies
Abstract Number: 0210

Longitudinal T Cell Responses to a Series of Four SARS-CoV-2 Vaccine Doses or COVID-19 in Patients on TNF Inhibitors
Abstract Number: 0211

COVID-19 Outcome and Association to Anti-Spike Antibody Levels in Patients on Immunosuppressive Therapy; A Prospective Cohort Study
Abstract Number: 0212

The Impact of Immunosuppression on the Humoral Immunogenicity of SARS-CoV-2 mRNA Vaccines in SLE
Abstract Number: 0213

When Should I Get My Next Booster? Active Surveillance of COVID-19 Breakthrough Infections in Canadian Patients with Immune-Mediated Inflammatory Diseases
Abstract Number: 0214

COVID-19 Vaccine Uptake, Hesitancy, and Flare in a Large Rheumatology Practice Network
Abstract Number: 0215

Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort
Abstract Number: 0216

High Immunogenicity of mRNA Covid-19 Vaccine Booster in Immune Mediated Inflammatory Disease
Abstract Number: 0217

Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study
Abstract Number: 0218

Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].